Latest Cancer News

Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer (10-16-2017)

Recent successes in genetically targeted precision cancer medicines are improving outcomes in a number of cancers.  Ensuring patients undergo genomic sequencing to determine if they have treatable targets is increasingly important to ensure patients receive the most appropriate personalized care. Precision cancer medicine utilizes molecular diagnostic testing, including DNA sequencing, [...]


Immunotherapy Active Against Triple-Negative Breast Cancer (10-12-2017)

October is breast cancer awareness month and patients with triple-negative breast cancer (TNBC) should be aware that data from two clinical trials provide additional evidence that they may derive benefit from checkpoint inhibitor therapy.1-4 About Triple Negative Breast Cancer Approximately 12% of breast cancers are triple-negative breast cancers, meaning that [...]


LynparzaTM Slows Spread of Inherited Breast Cancer Caused By BRCA Mutations (10-10-2017)

LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes also appears to slowe the progression of breast cancer caused in part by mutations in the BRCA gene.  BRCA is an inherited condition that causes up to 3% of all breast cancers. BRCA [...]


FDA approves new treatment for certain advanced or metastatic breast cancers (10-5-2017)

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy). Verzenio is approved to be given [...]


FDA Approves Aliqopa for Relapsed Follicular Lymphoma (10-4-2017)

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), an intravenously administered pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies. Follicular lymphoma is the most common indolent (slow-growing) form of [...]


New Standard of Care for Treatment of Resectable Gastric Cancer (10-3-2017)

The superiority of docetaxel based triplet therapy over standard care in patients with resectable esophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid.1 Survival in resectable esophago-gastric cancer is poor. Five-year overall survival is around 25% with surgery, and [...]


Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma (09-28-2017)

Adjuvant treatment with the immunotherapy drug Opdivo (nivolumab) is superior to Yervoy (ipilimumab) for the management of stage IIIb/c or stage IV melanoma following complete surgical resection. These important results were presented at the European Society for Medical Oncology and published simultaneously in the New England Journal of Medicine. There [...]


The US Food and Drug Administration has Expanded the Approval of the Precision Cancer Medicine Keytruda for Treatment of Gastric Cancer (09-25-2017)

Keytruda (Pembrolizumab) is now indicated for patients with recurrent locally advanced or metastatic gastric or gastro-esophogeal junction adenocarcinoma. Patients eligible for keytruda therapy under this new indication must have PD-L1-expressing tumors, and must demonstrate disease progression after two or more prior lines of therapy – including fluoropyrimidine- and platinum-containing chemotherapy [...]


FDA Adds Two Roche Multiple Myeloma Studies Evaluating Checkpoint Inhibitors to List of Partial Clinical Holds Over Safety Concerns (09-25-2017)

Alarmed that an imbalance in deaths among patients taking a combination of Keytruda (pembrolizumab) with Celgene’s Pomalyst and Revlimid could represent a threat in that whole class of checkpoint comboinations, the FDA has added two Tecentriq (atezolizumab) clinical studies to its growing list of clinical trials placed on partial hold [...]


Alecensa Appears Superior to Xalkori in ALK positive NSCLC Involving the Brain (09-21-2017)

The results from two separate clinical studies comparing Alecensa® (alectinib) to Xalkori (crizotinib) presented at the European Society for Medical Oncology in Madrid demonstrate that Alecensa®  s superior in treating non small cell lung caner (NSCLC) that has spread to the brain in anaplastic lymphoma kinase (ALK) gene positive NSCLC. [...]


Lower Thyroid Stimulating Hormone Levels Elevate Risk of Thyroid Cancer (09-20-2017)

There is an increased risk of thyroid cancer associated with lower-than-normal thyroid hormone levels, a finding that could have a major impact on patients fighting the disease. The Yale-led study, published in American Association for Cancer Research journal examined the effect of Thyroid Stimulating Hormone (TSH) on the development of [...]


Pass it On: It’s Leukemia National Awareness Month (09-19-2017)

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will be 60,140 new cases of leukemia and 24,400 deaths in 2016. For lymphoma, the ACS estimates that 81,080 new cases and 21,270 deaths will occur [...]


Next Page »